ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
Delayed Nasdaq  -  04:00 2022-08-16 pm EDT
14.62 USD   -3.43%
10:24aALX Oncology's Evorpacept Picked for New Treatment Arm in Breast Cancer Trial
MT
09:55aALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer
PR
08/15ALX ONCOLOGY : Corporate Presentation
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Cantor Fitzgerald Adjusts Price Target for ALX Oncology to $60 From $103, Maintains Overweight Rating

03/14/2022 | 11:59am EDT


© MT Newswires 2022
All news about ALX ONCOLOGY HOLDINGS INC.
10:24aALX Oncology's Evorpacept Picked for New Treatment Arm in Breast Cancer Trial
MT
09:55aALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of..
PR
08/15ALX ONCOLOGY : Corporate Presentation
PU
08/15ALX Oncology Says Evorpacept Selected in Early-Stage Trial in Combination With Enhertu ..
MT
08/15ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of..
GL
08/15ALX Oncology Holdings Inc. and Quantum Leap Healthcare Collaborative Announces the Sele..
CI
08/11First Patient Dosed in ALX Oncology's Mid-Stage Trial of Colorectal Cancer Combination ..
MT
08/11ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of E..
GL
08/11ALX Oncology Holdings Inc. Announces First Patient Dosed in Phase 2 Investigator-Sponso..
CI
08/09Cantor Fitzgerald Adjusts ALX Oncology Holdings' Price Target to $32 from $60, Maintain..
MT
More news
Analyst Recommendations on ALX ONCOLOGY HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -126 M - -
Net cash 2022 262 M - -
P/E ratio 2022 -5,01x
Yield 2022 -
Capitalization 596 M 596 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 52
Free-Float 62,5%
Chart ALX ONCOLOGY HOLDINGS INC.
Duration : Period :
ALX Oncology Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALX ONCOLOGY HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 14,62 $
Average target price 38,88 $
Spread / Average Target 166%
EPS Revisions
Managers and Directors
Jaume Pons President, Chief Executive Officer & Director
Peter S. García Chief Financial Officer
Corey S. Goodman Executive Chairman
Sophia Randolph Director & Chief Medical Officer
Michael Chang Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ALX ONCOLOGY HOLDINGS INC.-29.55%617
GILEAD SCIENCES, INC.-8.81%82 985
VERTEX PHARMACEUTICALS39.13%78 356
REGENERON PHARMACEUTICALS, INC.1.86%68 773
WUXI APPTEC CO., LTD.-23.26%40 492
BIONTECH SE-36.97%39 486